Skip to Content

Are you based in North America? If yes, switch to our North American website →

IGL Breakapart

Applications
haematology
Catalogue Numbers
LPH 033-S (5 tests)
LPH 033 (10 tests)

Probe Specification

  • IGL, 22q11.21-q11.23, Red
  • IGL, 22q11.21-q11.23, Green

The IGL product consists of a 278kb probe, labelled in red, centromeric to the IGL Variable region and covering the MAPK1 gene, and a green probe, covering a 307kb region telomeric to the IGL Constant segment, including the BCR gene.

Probe Information

Recurrent rearrangements involving the IGL (immunoglobulin lambda locus) gene at 22q11, with a wide range of partner genes, are seen in lymphomas and haematological malignancies.

A large number of B-cell malignancies harbour translocations involving the immunoglobulin (IG) loci. The majority of cases will show rearrangements involving the IGH gene; however, variant translocations have been described in 5-10% of B-cell neoplasms which involve either the immunoglobulin kappa (IGK) light chain locus at 2p11.2 or the immunoglobulin lambda (IGL) light chain locus at 22q111,2.

Variant translocations involving the IG light chain loci are seen in Burkitt lymphoma and multiple myeloma, with the presence of a t(2;8)(p12;q24) MYC-IGK, or t(8;22)(q24;q11) MYC-IGL3,5. In diffuse large B-cell lymphoma (DLBCL), translocations may involve the BCL6 gene via t(2;3)(p12;q27) or t(3;22)(q27;q11) translocations, or the BCL2 gene via t(2;18)(p12;q21) or t(18;22)(q21;q11) translocations6.

In our hands, Cytocell FISH probes, have proven to be of the highest quality with bright, easy to interpret signals, thus providing confidence in our results. Cytocell’s customer support is outstanding, as their staff are extremely knowledgeable and truly care about their customers and their customers’ needs. Jennie Thurston, Director of Cytogenetics at Carolinas Pathology Group

References

  1. Poulseu TS et al., Leukemia 2002;16:2148-55
  2. Martin-Subero JI et al., Int J Cancer 2002;98:470-4
  3. Kornblau SM et al., Hematol Oncol 1991;9:63-78
  4. Walker BA, et al., Blood Cancer J; 2014;4(3):e191
  5. Chaganti SR et al., Genes Chromosomes Cancer 1998;23:323-7
  6. Tashiro S et al., Oncogene 1992;7:573-7
  7. Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The AGT Cytogenetics Laboratory Manual. New Jersey: John Wiley & Sons Inc.
  8. Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13(7):667-675.
  9. Wiktor AE, Dyke DLV, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM, Fink SR, Stockero KJ, Majorowicz JR, Dewald GW. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genetics in Medicine. 2006;8(1):16–23.

Microscope Images

IGL Breakapart magnified
Area of Interest*
Lymphoma

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.